Curcumin (Curcuma longa extract)

Herbal anti-inflammatory agents

ATC code: A07XA-CURCUMIN (Curcumin (Curcuma longa extract) – local code)

Brand names – supplements

Curcumin C3 Complex, Meriva (Indena), Theracurmin HP, Thorne Meriva 500-SF, Doctor's Best High Absorption Curcumin

Supplements are not tested in clinical trials and are not registered as medications.

Mechanism of action

Curcumin is the main active component of turmeric root (Curcuma longa). Inhibits the transcription factor NF-κB, pro-inflammatory cytokine synthesis (TNF-α, IL-1, IL-6), and COX-2 and lipoxygenase activity. In vitro, it demonstrates antioxidant, anti-inflammatory, and antifibrotic effects. The main clinical limitation is extremely low oral bioavailability of pure curcumin (less than 1%) due to poor absorption, rapid metabolism, and systemic elimination. Bioavailability is increased in formulations with piperine, phospholipids (Meriva), or nanoparticles.

Indications

Knee osteoarthritis

Not recommended

The Foods 2021 systematic review (16 RCTs, more than 1,800 patients) showed moderate reductions in pain intensity and functional improvement in knee osteoarthritis patients on curcumin 500–1,500 mg daily for 8–12 weeks. Study quality is moderate, many manufacturer-funded, samples small. ACR 2019 does not recommend curcumin for osteoarthritis. OARSI 2019 does not include curcumin in standards. Standard therapy: physical rehabilitation, paracetamol, NSAIDs, intra-articular injections when needed, and joint replacement.

Sources

Ulcerative colitis remission maintenance

Adjunct

The 2020 Cochrane review (7 RCTs, more than 380 patients) showed a moderate reduction in ulcerative colitis relapse rate with curcumin 1–3 g daily added to baseline mesalazine therapy. The effect is confirmed in small RCTs and requires reproduction in large multicentre trials. Major societies (AGA, ECCO) do not include curcumin in UC management standards. Decisions are individualised with a gastroenterologist.

Sources

Anti-aging and longevity (marketed indication)

Not recommended

Curcumin for slowing ageing, extending lifespan, or supporting cognition in healthy people is not mentioned in international guidelines. The “universal antioxidant” marketing position lacks clinical confirmation. Pure curcumin bioavailability is extremely low, and standard supplement doses are unlikely to achieve the systemic concentrations shown in laboratory models.

Sources

Foods: Curcumin in the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis (2021)

Cancer prevention

Not recommended

Curcumin for cancer prevention in people without an established diagnosis is not mentioned in international guidelines. Laboratory antitumour data have not translated to clinical practice – large positive RCTs on cancer incidence or mortality are absent. In patients with active cancer on chemotherapy or targeted therapy, curcumin use should be discussed with the treating oncologist due to potential drug interactions.

Sources

Foods: Curcumin in the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis (2021)

Major depressive disorder

Not recommended

Curcumin as monotherapy or adjunct in major depression is not mentioned in international psychiatric guidelines (APA, NICE mental health). Small RCTs showed a weak effect on mild-to-moderate depression symptoms in combination with standard therapy – not reproduced in large RCTs. Standard depression therapy: psychotherapy and/or antidepressants, not curcumin.

Sources

Foods: Curcumin in the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis (2021)

Practical notes

Timing and administration

Take with food, preferably one containing fat – curcumin is fat-soluble and absorption increases 5–10 fold with fat. Combination with piperine (10 mg) increases bioavailability 20-fold via inhibition of hepatic and intestinal glucuronidation. Meriva (phospholipid complex) and Theracurmin (nanoparticles) provide 30–80 fold higher systemic bioavailability than pure curcumin.

Dose titration

Standard standardised Curcuma longa extract dose (95% curcuminoids): 500–1,500 mg daily in 1–3 portions. Enhanced-bioavailability formulations (Meriva, BCM-95, Theracurmin): 200–500 mg daily equivalent in effect. Dietary turmeric (rice and vegetable seasoning) provides 50–200 mg curcumin at typical consumption frequencies.

Monitoring

At 8–12 weeks, assess clinical effect. If no improvement, discontinue. Monitor ALT and AST during long-term therapy – rare cases of drug-induced hepatitis on curcumin are reported, especially with enhanced-bioavailability formulations. Monitor INR in patients on warfarin – curcumin can enhance the anticoagulant effect.

Food and drinks

Dietary source: turmeric root (spice). 1 teaspoon (3 g) of dried turmeric contains 60–100 mg curcuminoids. Bioavailability from the spice is low without combination with fat and black pepper (piperine). In Indian and Thai cuisines, turmeric is regularly added to curries and stews – estimated average intake in these regions is 60–100 mg curcuminoids daily. Intake in other regions is much lower.

Common myths

Myth: “curcumin treats everything – from cancer to depression”. Fact: laboratory data on antitumour, anti-inflammatory, and neuroprotective effects do not translate to clinical practice. Pure curcumin bioavailability is less than 1%, and systemic concentrations at standard doses are insufficient to reproduce in vitro effects.

Myth: “curcumin with piperine is a mandatory combination”. Fact: piperine increases curcumin bioavailability 20-fold, but is also a potent CYP3A4 and P-glycoprotein inhibitor. This creates a risk of drug interactions with many medicines (statins, immunosuppressants, antidepressants, warfarin). In polypharmacy, the curcumin+piperine combination requires caution.

Myth: “golden milk heals joints”. Fact: the effect of dietary turmeric on joints is clinically minor. The curcuminoid dose in a standard cup of golden milk is 50–100 mg, 5–15 times less than RCT-tested doses. With osteoarthritis and pain, consult a clinician for standard therapy, not spices.

Safety

Contraindications

Hypersensitivity to curcumin or turmeric
Pregnancy and breastfeeding
Active cholelithiasis
Acute cholangitis, biliary obstruction
Severe liver disease
Concomitant anticoagulant therapy (requires INR monitoring)

Serious adverse effects

Drug-induced hepatitis – rare but reported with enhanced-bioavailability formulations (Meriva, Theracurmin)
Increased warfarin anticoagulant effect with bleeding risk
Drug interactions via CYP3A4 inhibition (especially with piperine)

Common adverse effects

Nausea, epigastric discomfort
Diarrhoea at high doses
Yellow stool discoloration

Uncommon adverse effects

Skin allergic reactions
Headache
Altered taste

PregnancyFDA C

Turmeric at culinary doses is safe. High-dose curcumin supplements in pregnancy are not recommended – there are theoretical data on uterine contractility stimulation and bleeding risk.

Breastfeeding

Turmeric at culinary doses is safe. High-dose curcumin supplements during breastfeeding are not recommended.